JP2012504393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504393A5 JP2012504393A5 JP2011529472A JP2011529472A JP2012504393A5 JP 2012504393 A5 JP2012504393 A5 JP 2012504393A5 JP 2011529472 A JP2011529472 A JP 2011529472A JP 2011529472 A JP2011529472 A JP 2011529472A JP 2012504393 A5 JP2012504393 A5 JP 2012504393A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- seq
- tumor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 208000005017 glioblastoma Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102100028743 CAP-Gly domain-containing linker protein 2 Human genes 0.000 claims 3
- 102100024074 Dystrobrevin alpha Human genes 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 101000767059 Homo sapiens CAP-Gly domain-containing linker protein 2 Proteins 0.000 claims 3
- 101001053689 Homo sapiens Dystrobrevin alpha Proteins 0.000 claims 3
- 101001108364 Homo sapiens Neuronal cell adhesion molecule Proteins 0.000 claims 3
- 101000633503 Homo sapiens Nuclear receptor subfamily 2 group E member 1 Proteins 0.000 claims 3
- 101000600766 Homo sapiens Podoplanin Proteins 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 claims 3
- 102100029534 Nuclear receptor subfamily 2 group E member 1 Human genes 0.000 claims 3
- 102100037265 Podoplanin Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000027831 neuroepithelial neoplasm Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000004066 Ganglioglioma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000005476 astroblastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000004058 mixed glioma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08017305.7 | 2008-10-01 | ||
| EP20080017305 EP2172211B1 (en) | 2008-10-01 | 2008-10-01 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| EP08017921.1A EP2172212B1 (en) | 2008-10-01 | 2008-10-13 | Novel immunotherapy against several tumors including neuronal and brain tumors |
| EP08017921.1 | 2008-10-13 | ||
| US10592808P | 2008-10-16 | 2008-10-16 | |
| US61/105,928 | 2008-10-16 | ||
| PCT/EP2009/006980 WO2010037514A2 (en) | 2008-10-01 | 2009-09-28 | Novel immunotherapy against several tumors including neuronal and brain tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014126001A Division JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504393A JP2012504393A (ja) | 2012-02-23 |
| JP2012504393A5 true JP2012504393A5 (enExample) | 2013-05-23 |
| JP5855940B2 JP5855940B2 (ja) | 2016-02-09 |
Family
ID=40342382
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529471A Expired - Fee Related JP5753783B2 (ja) | 2008-10-01 | 2009-09-28 | 神経膠芽細胞腫（ｇｂｍ）およびその他の癌の治療に用いる腫瘍関連ペプチド組成物と関連抗癌ワクチン |
| JP2011529472A Expired - Fee Related JP5855940B2 (ja) | 2008-10-01 | 2009-09-28 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529471A Expired - Fee Related JP5753783B2 (ja) | 2008-10-01 | 2009-09-28 | 神経膠芽細胞腫（ｇｂｍ）およびその他の癌の治療に用いる腫瘍関連ペプチド組成物と関連抗癌ワクチン |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014126001A Expired - Fee Related JP5883476B2 (ja) | 2008-10-01 | 2014-06-19 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2015200021A Active JP6150859B2 (ja) | 2008-10-01 | 2015-10-08 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016021002A Expired - Fee Related JP6214066B2 (ja) | 2008-10-01 | 2016-02-05 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136515A Expired - Fee Related JP6367266B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136518A Expired - Fee Related JP6294914B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136517A Expired - Fee Related JP6294913B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136519A Expired - Fee Related JP6297632B2 (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
| JP2016136516A Pending JP2017029135A (ja) | 2008-10-01 | 2016-07-11 | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (19) | US8119139B2 (enExample) |
| EP (12) | EP2172211B1 (enExample) |
| JP (10) | JP5753783B2 (enExample) |
| KR (6) | KR101883426B1 (enExample) |
| CN (3) | CN102170901B (enExample) |
| AU (2) | AU2009300087B2 (enExample) |
| BR (2) | BRPI0920791B8 (enExample) |
| CA (9) | CA2936982C (enExample) |
| CY (11) | CY1116302T1 (enExample) |
| DK (12) | DK2172211T3 (enExample) |
| EA (3) | EA023378B1 (enExample) |
| ES (12) | ES2536465T3 (enExample) |
| HR (12) | HRP20170115T1 (enExample) |
| HU (11) | HUE031030T2 (enExample) |
| LT (10) | LT2172212T (enExample) |
| MX (3) | MX338294B (enExample) |
| NZ (4) | NZ603016A (enExample) |
| PL (12) | PL2172211T3 (enExample) |
| PT (12) | PT2172211E (enExample) |
| RS (12) | RS53782B1 (enExample) |
| SI (12) | SI2172211T1 (enExample) |
| TR (2) | TR201900809T4 (enExample) |
| UA (3) | UA125277C2 (enExample) |
| WO (2) | WO2010037513A1 (enExample) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012079878A2 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2006023598A2 (en) | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| CN103911358B (zh) * | 2007-07-27 | 2017-03-01 | 伊玛提克斯生物技术有限公司 | 神经元和脑肿瘤的新型免疫疗法 |
| SI2113253T1 (sl) | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| SE535982C2 (sv) * | 2009-12-15 | 2013-03-19 | Theravac Pharmaceuticals Ab | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| DK2608799T3 (en) * | 2010-08-24 | 2019-03-18 | Univ Pittsburgh Commonwealth Sys Higher Education | INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES |
| WO2012075490A2 (en) * | 2010-12-03 | 2012-06-07 | Duke University | Anti-podoplanin antibodies and methods of use |
| US20140154269A1 (en) * | 2011-04-26 | 2014-06-05 | The Methodist Hospital Research Institute | Targeted nanovectors and their use for treatment of brain tumors |
| JP2014526517A (ja) * | 2011-09-14 | 2014-10-06 | ノースウェスタン ユニバーシティ | 血液脳関門を通過することができるナノ抱合体 |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| MX367614B (es) | 2012-01-20 | 2019-08-28 | Del Mar Pharmaceuticals | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN103372217B (zh) * | 2012-04-28 | 2014-12-10 | 中国科学院深圳先进技术研究院 | 聚合物纳米载体制剂及其制备方法和应用 |
| SI3536334T1 (sl) * | 2012-05-16 | 2021-11-30 | Stemline Therapeutics Inc. | Cepiva proti raku, ki ciljajo na rakave matične celice |
| CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| KR102383710B1 (ko) | 2013-08-05 | 2022-04-08 | 이매틱스 바이오테크놀로지스 게엠베하 | Nsclc를 포함하는 폐암과 같은 여러 가지 종양에 대한 면역요법 |
| MX2019013161A (es) * | 2013-11-04 | 2020-02-03 | Immatics Biotechnologies Gmbh | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| CN104698059B (zh) * | 2013-12-04 | 2017-07-21 | 苏州中赢医疗科技有限公司 | 一种脑胶质瘤肿瘤标志物及其应用 |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| KR101503341B1 (ko) * | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| CA2946552A1 (en) | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| SG10201809379UA (en) | 2014-04-25 | 2018-11-29 | Bluebird Bio Inc | Mnd promoter chimeric antigen receptors |
| WO2015182668A1 (ja) * | 2014-05-28 | 2015-12-03 | 学校法人東京女子医科大学 | 膠芽腫の予測方法 |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| SMT202100049T1 (it) * | 2014-06-06 | 2021-03-15 | Bluebird Bio Inc | Composizioni di cellule t migliorate |
| JP6366379B2 (ja) * | 2014-06-20 | 2018-08-01 | キヤノン株式会社 | 被検体情報取得装置 |
| SG11201700492SA (en) | 2014-07-24 | 2017-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| WO2016070928A1 (en) * | 2014-11-06 | 2016-05-12 | Orphan Synergy Europe - Pharma | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis |
| WO2016094304A2 (en) | 2014-12-12 | 2016-06-16 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| PL3545965T3 (pl) * | 2014-12-23 | 2021-12-27 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| MY199500A (en) | 2015-03-17 | 2023-11-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN107810193B (zh) * | 2015-05-06 | 2022-03-22 | 伊玛提克斯生物技术有限公司 | 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| US11305002B2 (en) | 2015-06-09 | 2022-04-19 | The Board Of Regents Of The University Of Oklahoma | Compositions and treatments for Haemophilus influenzae |
| ES2879248T3 (es) | 2015-06-24 | 2021-11-22 | Immodulon Therapeutics Ltd | Inhibidor de puntos de control y micobacteria de célula completa para su uso en terapia contra el cáncer |
| PE20230321A1 (es) | 2015-07-01 | 2023-02-22 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MX2017017148A (es) * | 2015-07-06 | 2018-02-23 | Immatics Biotechnologies Gmbh | Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres. |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| PH12018501893A1 (en) | 2015-08-28 | 2022-05-02 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| JP7572700B2 (ja) | 2015-10-19 | 2024-10-24 | ユニバーシティ オブ メリーランド ボルチモア | 改変ヒト初代血液樹状細胞株を生成するための方法 |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| HK1255541A1 (zh) * | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| TWI765875B (zh) | 2015-12-16 | 2022-06-01 | 美商磨石生物公司 | 新抗原辨識、製造及用途 |
| WO2017123996A1 (en) | 2016-01-15 | 2017-07-20 | City Of Hope | Targeting glioblastoma stem cells through the tlx-tet3 axis |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| CN109620949A (zh) * | 2016-03-13 | 2019-04-16 | 曹帅 | 一种用于治疗骨癌的药物组合物 |
| GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| LT3430037T (lt) | 2016-03-16 | 2022-12-12 | Immatics Biotechnologies Gmbh | Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją |
| GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| CN109071605A (zh) * | 2016-04-06 | 2018-12-21 | 伊玛提克斯生物技术有限公司 | 用于aml和其他癌症免疫治疗的新型肽和肽组合物 |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2017194170A1 (en) * | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| KR101881300B1 (ko) | 2016-06-30 | 2018-07-25 | 영남대학교 산학협력단 | 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법 |
| CN110022889B (zh) * | 2016-10-03 | 2024-05-10 | 渥太华医院研究所 | 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法 |
| US12109234B2 (en) | 2016-11-04 | 2024-10-08 | 2Seventy Bio, Inc. | Anti-BCMA CAR T cell compositions |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| US20190352363A1 (en) | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| BR112019007714B1 (pt) | 2017-01-06 | 2022-01-18 | Eutilex Co., Ltd | Anticorpos anti-4-1bb, uso do mesmo, composição farmacêutica, métodos para determinar uma dose, para aumentar a secreção de ifn-gama por uma célula in vitro e para proliferação ex vivo ou isolamento de células t ativadas e uso das mesmas |
| GB201702863D0 (en) * | 2017-02-22 | 2017-04-05 | Evox Therapeutics Ltd | Improved loading of EVs with therapeutic proteins |
| US20180248175A1 (en) * | 2017-02-28 | 2018-08-30 | Lyten, Inc. | Mixed allotrope particulate carbon films and carbon fiber mats |
| WO2018208856A1 (en) * | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| CN107058596A (zh) * | 2017-06-19 | 2017-08-18 | 上海市第十人民医院 | 一种与恶性胶质瘤诊断相关的标志物及其应用 |
| CN107034305A (zh) * | 2017-06-19 | 2017-08-11 | 上海市第十人民医院 | 恶性胶质瘤的一种诊断标志物 |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3724327A4 (en) * | 2017-12-14 | 2022-01-12 | EZY Biotech LLC | SUBJECT-SPECIFIC TUMOR-INHIBITING CELLS AND THEIR USE |
| DK3773689T5 (da) * | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| CN108715832B (zh) * | 2018-06-01 | 2020-11-10 | 段海峰 | 一种抑制肿瘤生长的间充质干细胞及制备方法和应用 |
| JP2021530218A (ja) | 2018-07-11 | 2021-11-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血液脳関門を超える薬剤の送達のための方法および組成物 |
| WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
| RU2706554C1 (ru) * | 2018-12-13 | 2019-11-19 | Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ | Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов |
| CN109796536B (zh) * | 2019-02-22 | 2021-09-17 | 上海尚泰生物技术有限公司 | 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法 |
| WO2020201048A1 (en) | 2019-03-29 | 2020-10-08 | Intervet International B.V. | Stabilisation of live mollicutes bacteria in a liquid composition |
| GB2617512B (en) * | 2019-04-05 | 2023-12-27 | Earli Inc | Improved methods and compositions for synthetic biomarkers |
| AU2020284538B2 (en) | 2019-05-28 | 2022-03-24 | PAIGE.AI, Inc. | Systems and methods for processing images to prepare slides for processed images for digital pathology |
| KR20220016137A (ko) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | 변형된 아데노바이러스 |
| CN110579457B (zh) * | 2019-09-20 | 2021-11-02 | 郑州大学第一附属医院 | 波形蛋白特异响应性荧光探针及其制备方法和应用 |
| CN112824427B (zh) * | 2019-11-18 | 2022-06-24 | 杨小骏 | 一种抑制胶质瘤的短肽及其应用 |
| KR20220127847A (ko) * | 2020-01-10 | 2022-09-20 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물 |
| WO2021173193A1 (en) * | 2020-02-24 | 2021-09-02 | The Regents Of The University Of California | Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain |
| CN113318225B (zh) * | 2020-02-28 | 2024-01-19 | 无锡派列博生物医药科技有限公司 | 肿瘤免疫增强剂及其制法和应用 |
| CN113444149A (zh) * | 2020-03-18 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用 |
| AU2021249123A1 (en) * | 2020-03-31 | 2022-10-27 | Walking Fish Therapeutics | Modified B cells and methods of use thereof |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| KR102711471B1 (ko) | 2020-08-14 | 2024-09-30 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| EP4203994A4 (en) * | 2020-08-28 | 2024-07-03 | Torigen Pharmaceuticals, Inc. | Immune memory enhanced preparations and uses thereof |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| WO2022192457A1 (en) * | 2021-03-09 | 2022-09-15 | Bostongene Corporation | Predicting response to treatments in patients with clear cell renal cell carcinoma |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| US20250235517A1 (en) * | 2022-03-30 | 2025-07-24 | Iogenetics, Llc | Tumor-associated antigens in brain tumors |
| PL441229A1 (pl) * | 2022-05-19 | 2023-11-20 | Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk | Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych |
| KR102907303B1 (ko) | 2024-12-23 | 2025-12-31 | 전남대학교산학협력단 | 다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법 |
| CN120272531B (zh) * | 2025-06-10 | 2025-08-19 | 鼐济医药科技(杭州)有限公司 | 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| GR73675B (enExample) | 1978-12-22 | 1984-03-29 | Biogen Inc | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5338839A (en) * | 1988-04-12 | 1994-08-16 | Massachusetts Institute Of Technology | DNA encoding nestin protein |
| KR100235089B1 (en) | 1992-05-14 | 1999-12-15 | Mitsui Chemicals Inc | Ptp or blister packaging articles and packaging material therefor |
| GB2267257A (en) | 1992-05-14 | 1993-12-01 | Ford Motor Co | A vehicle load compartment liner. |
| ES2138662T3 (es) | 1993-06-03 | 2000-01-16 | Therapeutic Antibodies Inc | Produccion de fragmentos de anticuerpos. |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| TW575583B (en) * | 1996-04-24 | 2004-02-11 | Akzo Nobel Nv | Novel peptides suitable for use in antigen specific immunosuppressive therapy |
| WO1998003197A1 (en) * | 1996-07-22 | 1998-01-29 | The Rockefeller University | Env-glycoprotein vaccine for protection of htlv-i and -ii infection |
| AU6240798A (en) | 1997-01-15 | 1998-08-07 | Zymogenetics Inc. | Zppar6, human tailless nuclear hormone receptor (tlx receptor) |
| EP0910641A1 (en) * | 1997-02-13 | 1999-04-28 | Smithkline Beecham Plc | Neural cell adhesion molecule splicing variants |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1999028349A2 (en) * | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
| US7258860B2 (en) * | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20070004655A9 (en) * | 1998-04-27 | 2007-01-04 | Murphy Gerald P | Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors |
| US20030082586A1 (en) * | 1999-06-29 | 2003-05-01 | Millennium Pharmaceuticals, Inc. | Antibodies having diagnostic, preventive, therapeutic, and other uses |
| CA2395885A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20020042096A1 (en) * | 2000-01-31 | 2002-04-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| EP1294748B1 (en) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| WO2002020036A1 (de) * | 2000-09-06 | 2002-03-14 | Mueller Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP2295575A3 (en) * | 2000-12-04 | 2011-07-06 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP1379879A2 (en) * | 2000-12-08 | 2004-01-14 | Oxford GlycoSciences (UK) Limited | Diagnosis and treatment of alzheimer's disease |
| WO2002074237A2 (en) * | 2001-03-19 | 2002-09-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CA2364106A1 (fr) * | 2001-11-30 | 2003-05-30 | Christopher Gillberg | Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques |
| US6589642B1 (en) | 2001-12-21 | 2003-07-08 | Kloeckner Pentaplast Of America, Inc. | Three part high moisture barrier for packages |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| AU2003258134A1 (en) * | 2002-08-09 | 2004-02-25 | Applera Corporation | Lung cancer target proteins and use thereof |
| JP4721633B2 (ja) * | 2002-10-11 | 2011-07-13 | 財団法人癌研究会 | 血小板凝集促進活性を有する物質 |
| EP1576966A4 (en) * | 2002-12-27 | 2006-07-26 | Shenzhen Tsinghua Yuanxing Bio | PROCESS FOR PREPARING A VACCINE AND ANTITUMOR VACCINES |
| US20060241166A1 (en) | 2003-04-04 | 2006-10-26 | Pharmacyclica, Inc. | Sapphyrins and uses thereof |
| US7273980B2 (en) | 2004-01-13 | 2007-09-25 | Wardle Scott A | Position and velocity transducer using a phonograph disc and turntable |
| CA2554195C (en) * | 2004-01-23 | 2011-02-22 | Green Peptide Co., Ltd. | Peptide originating in epidermal growth factor receptor (egfr) |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006026569A2 (en) * | 2004-08-27 | 2006-03-09 | Northeastern University | Comprehensive characterization of complex proteins at trace levels |
| ES2319286T3 (es) * | 2004-10-02 | 2009-05-06 | Immatics Biotechnologies Gmbh | Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos. |
| WO2006062094A1 (ja) * | 2004-12-07 | 2006-06-15 | Toray Industries, Inc. | 新規癌抗原ペプチド及びその用途 |
| KR100809410B1 (ko) * | 2005-07-06 | 2008-03-05 | 주식회사 브레인가드 | 줄기세포 분화 유도용 조성물 및 그의 용도 |
| DK1760088T3 (da) | 2005-09-05 | 2008-06-09 | Immatics Biotechnologies Gmbh | Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler |
| EP1760089B1 (en) * | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| WO2007047796A2 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| WO2007072494A1 (en) | 2005-12-23 | 2007-06-28 | Naik Praful Ramchandra | Metallized packaging blister container |
| AU2007298494B2 (en) * | 2006-09-21 | 2013-09-26 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| CA2700573C (en) * | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008109757A2 (en) * | 2007-03-06 | 2008-09-12 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
| US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
| KR101184869B1 (ko) | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| SI2113253T1 (sl) * | 2008-04-30 | 2010-06-30 | Immatics Biotechnologies Gmbh | Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| ES2784500T3 (es) * | 2014-05-28 | 2020-09-28 | Nono Inc | Sal de cloruro de Tat-NR2B9c |
| BR112018070873A2 (pt) | 2016-04-21 | 2019-02-05 | Immatics Biotechnologies Gmbh | imunoterapia contra melanoma e outros cânceres |
| JP7382310B2 (ja) * | 2017-09-06 | 2023-11-16 | カリフォルニア インスティチュート オブ テクノロジー | シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ） |
-
2008
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
-
2009
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko active Active
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko active Active
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko active Active
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
-
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
-
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
-
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
-
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja active Active
-
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
-
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
-
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
-
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
-
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
-
2021
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504393A5 (enExample) | ||
| JP2017502076A5 (enExample) | ||
| JP2011520436A5 (enExample) | ||
| KR101391561B1 (ko) | Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물 | |
| TWI608099B (zh) | 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物 | |
| JP2020182458A5 (enExample) | ||
| HRP20161504T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga | |
| JP2018510628A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2010534464A5 (enExample) | ||
| JP2021101700A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| TW202110875A (zh) | 病毒載體及其在授受性細胞療法之應用 | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2018511321A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| JPWO2014098012A1 (ja) | ヘルパーｔ細胞の活性化方法 | |
| Cho et al. | Design of immunogenic and effective multi-epitope DNA vaccines for melanoma | |
| JP2019515653A5 (enExample) | ||
| CN106243213A (zh) | 一种肿瘤相关抗原XAGE‑1b短肽及应用 | |
| Bojarska et al. | Short Peptides as Powerful Arsenal for Smart Fighting Cancer | |
| TW202140539A (zh) | 一種辨識ａｆｐ抗原短鏈胜肽的ｔ細胞受體及其編碼序列 | |
| TW202140532A (zh) | 一種辨識afp的t細胞受體及其編碼序列 | |
| CN101041816B (zh) | 人工抗原递呈细胞及其制备方法 |